Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Our Company

Location Settings

North America

US -  Boston
US -  San Francisco

Oceania

NZ -  New Zealand
AU -  Brisbane
AU -  Melbourne
AU -  Sydney

Asia

TH -  Bangkok
CN -  Taipei City
KR -  Seoul
PH -  Metro Manila
MY -  Kuala Lumpur
IN -  Bangalore
CN -  Shanghai
CN -  Hong Kong

GLOBAL

English

SOLUTIONS

RESOURCES

ABOUT US

Location Settings

North America

US -  Boston
US -  San Francisco

Oceania

NZ -  New Zealand
AU -  Brisbane
AU -  Melbourne
AU -  Sydney

Asia

TH -  Bangkok
CN -  Taipei City
KR -  Seoul
PH -  Metro Manila
MY -  Kuala Lumpur
IN -  Bangalore
CN -  Shanghai
CN -  Hong Kong

GLOBAL

English

Novotech is internationally recognized as the leading regional full-service contract research organization (CRO).

Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech’s strong Asia Pacific presence includes running clinical trials in all key regional markets. Novotech also has worldwide reach through the company's network of strategic partners.

Novotech and PPC Group formed a strategic partnership in 2019 creating the largest biotech CRO specialist in the Asia-Pacific region. The partnership brings together approximately 1,200 staff to meet the growing biotech demand in the region.

Our Company

We've enjoyed exceptionally strong growth. But we remain very focused on our core mission, of being a full-service CRO, specializing in biotech sector sponsors conducting trials in the Asia-pacific region. Asia is a heterogenous environment with different cultures, languages, and regulatory environments. A core to our strategy is to have experienced local leadership and on-the-ground regulatory, and monitoring presence in each of the countries in which we operate. Our people have a deep understanding of their local environment and excellent English language capabilities.

- Dr. John Moller

Chief Executive Officer, Novotech CRO

Where We operate

  • Asia
  • North America
  • Oceania

Australia

  • High quality research, facilities and equipment
  • Fast set-up and approval times
  • Sponsor can claim R&D cash refund

Greater China

  • Very large, homogenous population
  • Strong focus of NMPA (previously CFDA) on shortening regulatory timelines
  • Largest clinical trial hub in Asia, with over 17,000 active investigators 
     
India

India

  • Large treatment-naïve population
  • High disease population load
  • The clinical activity grew by over 40% in 2018 on the back of regulatory pathway improvements
  • About 1,800 investigators have participated on a minimum of 5 studies

Malaysia

  • Multiethnic Asian population
  • Streamlined regulatory system and Strong govt. support 
  • Quick start-up timelines
  • Low patient costs and IRB fees

Philippines

  • Large treatment-naïve population
  • Low costs
  • Overall good level of English

Singapore

  • Multiethnic Asian population 
  • Regional clinical research hub
  • Efficient regulatory process and good infrastructure

South Korea

  • Homogenous and concentrated population 
  • High quality medical services and excellent infrastructure
  • The most active Asian country in clinical research after China, with over 400 sites opened by biopharmas companies in 2018

Thailand

  • Large homogenous population 
  • High prevalence of communicable diseases
  • Efficient regulatory system
  • Low operational cost

United States of America

 

Novotech has two customer facing offices
on both the East Coast and West Coast.

New Zealand

  • High-quality research, facilities and equipment
  • Fast set-up and approval times
  • Sponsor can claim R&D cash refund